One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Notably, this interview came following the Dec. 27, 2024, Food and Drug Administration (FDA) approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. Intravenous ...

The single ascending dose, multiple ascending dose, and dose-response study explored three distinct maintenance doses of one-time-a-week subcutaneous ... a high dose of Wegovy in the Phase IIIb ...

Doctor, nurse or patient. A woman in rubber medical gloves opens a syringe pen with a needle. Medication insulin, subcutaneous injection for diabetic. Diabetes treatment. Covid-19 vaccination, vaccine ...

Veru said Monday that its investigational drug helped preserve lean mass in patients taking the obesity treatment Wegovy, though some experts were skeptical that the topline results were adequate ...

Chief executive Chris Viehbacher said on Biogen's results call that a plan to extend the use of the subcutaneous injector into the induction phase of treatment could be a "game changer." ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version ... even at home using a self-injector. Alteogen will use its ...

The single ascending dose, multiple ascending dose, and dose-response study explored three distinct maintenance doses of one-time-a-week subcutaneous administration ... weight loss outcomes with a ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...